Forette F, Seux M L, Staessen J A, Thijs L, Birkenhäger W H, Babarskiene M R, Babeanu S, Bossini A, Gil-Extremera B, Girerd X, Laks T, Lilov E, Moisseyev V, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Fagard R
Department of Geriatrics, Hôpital Broca, University of Paris V, France.
Lancet. 1998 Oct 24;352(9137):1347-51. doi: 10.1016/s0140-6736(98)03086-4.
Systolic hypertension increases the risk of dementia in elderly people. The vascular dementia project, set up in the framework of the double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial, investigated whether antihypertensive drug treatment could reduce the incidence of dementia.
Eligible patients had no dementia, were at least 60 years old, and had a blood pressure when seated of 160-219 mm Hg systolic and below 95 mm Hg diastolic. Active treatment consisted of nitrendipine (10-40 mg/day) with the possible addition of enalapril (5-20 mg/day), hydrochlorothiazide (12.5-25 mg/day), or both drugs, titrated or combined to reduce the systolic blood pressure by at least 20 mm Hg to reach a value below 150 mm Hg. Cognitive function was assessed by the mini mental state examination (MMSE). If the MMSE score was 23 or less, diagnostic tests for dementia were done (DSM-III-R criteria). The cause of dementia was established by the modified ischaemic score with brain imaging or the Hachinski score.
Median follow-up by intention to treat was 2.0 years. Compared with placebo (n=1180), active treatment (n=1238) reduced the incidence of dementia by 50% from 7.7 to 3.8 cases per 1000 patient-years (21 vs 11 patients, p=0.05). The median MMSE score at randomisation was 29 in both treatment groups. At the last available assessment, systolic and diastolic blood pressure were, respectively, 8.3 mm Hg and 3.8 mm Hg lower (p<0.001) in the active-treatment group, but on average the MMSE scores did not change in either group. In the control patients, however, the MMSE decreased (p=0.04) with decreasing diastolic blood pressure, whereas in the active-treatment group MMSE scores improved slightly (p=0.01) with greater reduction in diastolic blood pressure (p=0.002 for between-group difference).
In elderly people with isolated systolic hypertension, antihypertensive treatment was associated with a lower incidence of dementia. If 1000 hypertensive patients were treated with antihypertensive drugs for 5 years 19 cases of dementia might be prevented.
收缩期高血压会增加老年人患痴呆症的风险。在双盲安慰剂对照的欧洲收缩期高血压(Syst-Eur)试验框架内设立的血管性痴呆项目,研究了抗高血压药物治疗是否能降低痴呆症的发病率。
符合条件的患者无痴呆症,年龄至少60岁,坐位时收缩压为160 - 219毫米汞柱,舒张压低于95毫米汞柱。积极治疗包括使用尼群地平(10 - 40毫克/天),可能加用依那普利(5 - 20毫克/天)、氢氯噻嗪(12.5 - 25毫克/天)或两种药物,通过滴定或联合使用使收缩压至少降低20毫米汞柱,达到低于150毫米汞柱的值。认知功能通过简易精神状态检查表(MMSE)进行评估。如果MMSE评分在23分及以下,则进行痴呆症诊断测试(DSM-III-R标准)。通过改良缺血评分结合脑成像或哈金斯基评分确定痴呆症的病因。
意向性治疗的中位随访时间为2.0年。与安慰剂组(n = 1180)相比,积极治疗组(n = 1238)使痴呆症发病率从每1000患者年7.7例降至3.8例,降低了50%(分别为21例和11例,p = 0.05)。两个治疗组随机分组时的MMSE中位评分均为29分。在最后一次可用评估时,积极治疗组的收缩压和舒张压分别低8.3毫米汞柱和低3.8毫米汞柱(p < 0.001),但两组的MMSE评分平均均未改变。然而,在对照组患者中,MMSE评分随舒张压降低而下降(p = 0.04),而在积极治疗组中,随着舒张压更大幅度降低(组间差异p = 0.002),MMSE评分略有改善(p = 0.01)。
在单纯收缩期高血压的老年人中,抗高血压治疗与较低的痴呆症发病率相关联。如果1000名高血压患者接受抗高血压药物治疗5年,可能预防19例痴呆症。